Results 231 to 240 of about 1,598,216 (309)

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray, Claire McNamara, Anna V. Chatzi   +2 more
wiley   +1 more source

Type 2 Diabetes Mellitus and Macrovascular Complications

International Journal of Endocrinology, 2017
Peng-Fei Shan, Qian Li, Mogher Khamaisi, Gui-fen Qiang   +3 more
doaj   +1 more source

Trends and future predictions of chronic kidney disease due to diabetes mellitus type 2 attributable to dietary risks: insights based on GBD 2021 data. [PDF]

Front Nutr
Xu M, Wei H, Lv D, Wei Y, Liu Z, Zhang Y, Liu Y.   +6 more
europepmc   +1 more source

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta, Ellen Brinza, Prateeti Khazanie, Pamela N. Peterson, P Michael Ho, David P. Kao   +5 more
wiley   +1 more source

Nutrient patterns and risk of diabetes mellitus type 2: a case-control study. [PDF]

BMC Endocr Disord
Haramshahi M, A-Elgadir TME, Daabo HMA, Altinkaynak Y, Hjazi A, Hjazi A, Saxena A, Najm MAA, Almulla AF, Alsaalamy A, Kashani MA.   +10 more
europepmc   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Normal triglyceride concentration and the risk of diabetes mellitus type 2 in the general population of China. [PDF]

Front Endocrinol (Lausanne)
Guo R, Wei L, Cao Y, Zhao W.
europepmc   +1 more source

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

ESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi, Mostafa Eslamiyeh, Amin Mansoori, Eisa Nazar, Maryam Alinezhad‐Namaghi, Reza Rezvani, Majid Ghayour‐Mobarhan, Habibollah Esmaily, Mohsen Moohebati, Gordon A. Ferns, Mark Ghamsary   +10 more
wiley   +1 more source

Connections between Cognitive Impairment and Atrial Fibrillation in Patients with Diabetes Mellitus Type 2. [PDF]

Biomedicines
Militaru M, Lighezan DF, Tudoran C, Militaru AG.   +3 more
europepmc   +1 more source